Tests CT0890B cell therapy in adults with relapsed or refractory acute myeloid leukemia
Tests CT0890B, modified immune cells, in adults with returning or resistant leukemia.
Plain-language title generated from the registry record
Registry title: Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 whose acute myeloid leukemia has come back or did not respond to treatment, and whose leukemia cells are NKG2D ligand-positive.
- Age
- 18 to 70 years
- Sex
- Men and women
- Disease stage
- Relapsed or refractory acute myeloid leukemia (AML) with at least 5% blasts in the bone marrow by morphology, and an expected survival of more than 12 weeks.
- Earlier treatment
- People cannot join if they had CAR-T therapy before, a stem cell transplant within 12 weeks, or earlier immunotherapy aimed at NKG2DL.
- Biomarker or test result
- The leukemia must be confirmed NKG2D ligand-positive.
Main reasons for not taking part
- Acute promyelocytic leukemia, BCR-ABL positive leukemia, or leukemia in the central nervous system
- History of epilepsy or other central nervous system disease
- Active graft-versus-host disease, or steroids taken by mouth or injection for it
- Active uncontrolled infection, or infection needing intravenous antibiotics or similar drugs
- Serious heart problems, such as NYHA class III-IV heart failure
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07617285, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07617285
- Record updated
- 1 June 2026
- Original description
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.Read full original descriptionShow less
A Phase I Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cells (CT0890B) in Patients With NKG2DL-Positive Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Inclusion: Age 18-70 years (inclusive), male or female; Relapsed or refractory acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, with confirmed NKG2D ligand-positive disease; Bone marrow blasts ≥5% by morphology; Estimated life expectancy >12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Adequate organ function without ongoing supportive care, defined as:; Cardiac: left ventricular ejection fraction (LVEF) ≥50%; Hepatic: ALT and AST ≤2.5 × upper limit of normal (ULN), and total bilirubin ≤2 × ULN; Renal: creatinine clearance ≥30 mL/min (calculated using the Cockcroft-Gault formula); Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN; Renal: creatinine clearance ≥30 mL/min (calculated using the Cockcroft-Gault formula); d) Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.
Exclusion: Participants who have previously received autologous or allogeneic CAR-T therapy; Participants who have received autologous stem cell transplantation or allogeneic stem cell transplantation within 12 weeks; Participants who have received prior immunotherapy targeting NKG2DL; Participant has clinically significant active GVHD or is receiving systemic corticosteroids for GVHD; History of myocardial infarction, coronary artery bypass grafting, or unstable angina within 6 months prior to Qinglin; Participants with a history of epilepsy or other central nervous system disease; Participant has any of the following at screening:; 1)Active, uncontrolled systemic infection or requiring intravenous anti-infective agents 2)Any of the following cardiac conditions, including:; New York Heart Association Class III-IV heart failure; History of uncontrolled arrhythmia of significant clinical significance (as judged by the investigator), such as ventricular arrhythmia; History of severe nonischemic ardiomyopathy; Other cardiac disease that the investigatorbelieve could jeopardize the participant 's well-being or compromise participation in this clinical trial; 3) Active bleeding of clinical significance as judged by the investigator; 4)Requiring supplemental oxygen to maintain oxygen saturation> 92%; 5)Patients with severe chronic obstructive pulmonary disease (COPD) or other lung diseases that cannot tolerate CAR-T treatment as judged by the investigator; Participants were diagnosed with acute promyelocytic leukemia (APL), BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), central nervous system leukemia.